Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Reexamination Certificate
2011-08-09
2011-08-09
Romeo, David (Department: 1647)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
C530S351000
Reexamination Certificate
active
07994281
ABSTRACT:
The present invention relates to novel methods for the design of proteins, in particular, cytokines. These methods allow the stabilisation of such cytokines, as well as modification of their selectivity/specificity for their cognate receptors. The invention also relates to various modified proteins that have been designed by the methods of the invention.
REFERENCES:
patent: 6740739 (2004-05-01), Ashkenazi et al.
patent: 2004/0146968 (2004-07-01), Chung et al.
patent: 2006/0141561 (2006-06-01), Kelley et al.
patent: 2007/0161564 (2007-07-01), Ashkenazi et al.
patent: 88/06625 (1988-09-01), None
patent: 99/36535 (1999-07-01), None
patent: 01/00832 (2001-01-01), None
patent: 03/029420 (2003-04-01), None
patent: 04/001009 (2003-12-01), None
Cha, SS et al., “2.8 Å Resolution Crystal Structure of Human TRAIL, a Cytokine with Selective Antitumor Activity,”Immunity, 1999, 11(2), 253-261.
Degli-Esposti et al., “Cloning and Characterization of TRAIL-R3, a Novel Member of the Emerging TRAIL Receptor Family,”J. Exp. Med., 1997, 186(7), 1165-1170.
Eck, MJ et al., “The Structure of Human Lymphotoxin (Tumor Necrosis Factor-β) at 1.9-Å Resolution,”J. Biol. Chem., 1992, 267(4), 2119-2122.
Filikov et al., “Computational stabilization of human growth hormone,”Protein Sci., 2002, 11, 1452-1461.
Hymowitz, S.G. et al., “A Unique Zinc-Binding Site Revealed by a High-Resolution X-ray Structure of Homotrimeric Apo2L/TRAIL,”Biochemistry, 2000, 39(4), 633-640.
Hymowitz, SG et al., “Triggering Cell Death: The Crystal Structure of Apo2L/TRAIL in a Complex with Death Receptor 5,”Mol. Cell., 1999, 4(4), 563-571.
Kelley, R.F. et al., “Receptor-selective mutants of Apo2L/TRAIL reveal a greater contribution of DR5 and DR4 to apoptosis signaling,” e-published ahead of print Nov. 1, 2004, Manuscript #M410660200v1, 1-41.
Luo et al., “Development of a cytokine analog with enhanced stability using computational ultrahigh throughput screening,”Protein Sci., 2002, 11, 1218-1226.
Mongkolsapaya, J. et al., “Structure of the TRAIL-DR5 complex reveals mechanisms conferring specificity in apoptotic initiation,”Nat. Struct. Biol., 1999, 6(11), 1048-1053.
Screaton et al., “TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL,”Curr. Biol., 1997, 7(9), 693-696.
Shanafelt, A.B. et al., “An immune cell-selective interleukin 4 agonist,”PNAS, 1998, 95(16), 9454-9458.
Van der Sloot, A. et al., “Stabilization of TRAIL, an all-β-sheet multimeric protein, using computational redesign,”Protein Engineering, Design&Selection, 2004, 17(9), 673-680.
Cool Robbert H.
Fernandez-Ballester Gregorio
Mullally Margaret M.
Quax Wilhelmus J.
Samali Afshin
European Molecular Biology Laboratory
Gamett Daniel C
National University of Ireland
Romeo David
University of Groningen
LandOfFree
Cytokine design does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cytokine design, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cytokine design will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2791188